Zymeworks (ZYME) Research & Development (2021 - 2026)
Zymeworks recorded quarterly Research & Development of $34.5 million in Q1 2026, up 10.32% quarter-over-quarter from $31.2 million in Q4 2025, and down 3.58% year-over-year from $35.7 million in Q1 2025.
Zymeworks' Research & Development history runs 6 years deep, the most recent figure standing at $34.5 million for Q1 2026.
- In Q1 2026, Research & Development fell 3.58% year-over-year to $34.5 million; the TTM figure through Mar 2026 stood at $135.7 million (down 1.88% YoY), while the FY2025 annual figure was $137.0 million, up 1.77% from the prior year.
- Research & Development came in at $34.5 million for Q1 2026 at Zymeworks, up from $31.2 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $62.5 million in Q1 2022 to a low of $25.5 million in Q4 2023.
- A 5-year average of $38.7 million and a median of $35.7 million in 2025 frame the typical range for Research & Development.
- Across the five-year window, Research & Development tumbled 51.81% in 2023 and surged 45.21% in 2024, its largest moves.
- Zymeworks' Research & Development stood at $53.0 million in 2022, then sank by 51.81% to $25.5 million in 2023, then soared by 45.21% to $37.1 million in 2024, then slipped by 15.72% to $31.2 million in 2025, then gained by 10.32% to $34.5 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $34.5 million, $31.2 million, and $35.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | 34.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.46 Mn |
| Dec 31, 2025 | 31.24 Mn |
| Sep 30, 2025 | 35.58 Mn |
| Jun 30, 2025 | 34.45 Mn |
| Mar 31, 2025 | 35.74 Mn |
| Dec 31, 2024 | 37.06 Mn |
| Sep 30, 2024 | 36.35 Mn |
| Jun 30, 2024 | 29.16 Mn |
| Mar 31, 2024 | 32.04 Mn |
| Dec 31, 2023 | 25.52 Mn |
| Sep 30, 2023 | 32.78 Mn |
| Jun 30, 2023 | 39.41 Mn |
| Mar 31, 2023 | 45.91 Mn |
| Dec 31, 2022 | 52.97 Mn |
| Sep 30, 2022 | 37.10 Mn |
| Jun 30, 2022 | 56.02 Mn |
| Mar 31, 2022 | 62.51 Mn |
| Dec 31, 2021 | 54.87 Mn |
| Sep 30, 2021 | 49.89 Mn |